Inactive Instrument

Press Releases KARA THER

Equities

KRTX

US48576A1007

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

KARA THER : Acquisition/Asset Disposal - Form 8-K	Mar. 18	PU
Karuna Therapeutics : Material Event - Form 8-K	Mar. 01	PU
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update	Feb. 22	BU
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX	Feb. 14	BU
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX	Dec. 31	BU
Bristol-Myers, Rocket Lab gain; Nike, Cummins Engine fall on Friday, 12/22/2023	Dec. 22	AQ
Stock market today: Wall Street ticks closer to record highs to cap its 8th straight winning week	Dec. 22	AQ
Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio	Dec. 22	AQ
KRTX STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Karuna Therapeutics, Inc. Is Fair to Shareholders	Dec. 22	BU
BMS strikes $14bn deal for Karuna Therapeutics	Dec. 22	AQ
Shareholder Alert: Ademi LLP investigates whether Karuna Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol-Myers	Dec. 22	PR
Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia	Dec. 14	BU
Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia	Nov. 29	BU
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia	Nov. 20	AQ
Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia	Nov. 16	BU
Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates	Nov. 02	BU
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress	Nov. 01	BU
Karuna Therapeutics to Present at Upcoming Investor Conferences	Nov. 01	BU
Karuna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023	23-10-19	BU
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology Congress	23-10-05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases KARA THER

Equities

KRTX

US48576A1007

Press Releases

Filters